PMI 8-K
Picard Medical, Inc. (PMI)
8-K
2026-07-21
For: 2026-07-17
View Original
Added on
July 21, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 17, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number) |
(IRS Employer
Identification No.)
|
|
|
|
(Address of principal executive offices, including zip code)
|
Registrant’s telephone number, including area code: (520 ) 545-1234
Not Applicable
(Former name or former address, if changed since last report)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On July 17, 2026, Picard Medical, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting'). All matters submitted for approval by the Company’s stockholders, as described in the Company’s proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on June 29, 2026, as amended by the additional definitive proxy materials filed with the SEC on July 8, 2026, were approved. The number of shares of common stock entitled to vote at the Company’s Annual Meeting was 102,695,935, representing the number of shares outstanding as of June 26, 2026, the record date for the Annual Meeting.
The results of the matters submitted to a shareholder vote at the Annual Meeting were as follows:
1. Election of directors. The following directors were elected for terms expiring at the 2027 annual meeting of stockholders:
| For | Against | Abstain | Broker Non-Votes | ||||
| Richard Fang | 54,158,482 | 2,316,008 | 213,115 | 2,282,437 | |||
| Sam Van | 56,317,177 | 154,508 | 215,920 | 2,282,437 | |||
| Joe Xiao | 54,033,717 | 2,438,262 | 215,626 | 2,282,437 | |||
| George Ye | 56,289,270 | 182,809 | 215,526 | 2,282,437 |
2. Approval, on an advisory basis, of the compensation of the Company’s named executive officers. The compensation of the Company’s named executive officers was approved.
| For | Against | Abstain | Broker Non-Votes | |||
| 56,104,172 | 490,596 | 92,837 | 2,282,437 |
3. Approval, on an advisory basis, of the frequency of future advisory votes on the compensation of the Company’s named executive officers. The frequency of every “one year” was approved.
| 1 Year | 2 Years | 3 Years | Abstain | Broker Non-Votes | ||||
| 56,309,300 | 152,766 | 105,108 | 120,431 | 2,282,437 |
Consistent with the stockholder vote, the Company’s board of directors determined that the Company will hold future advisory votes on the compensation of the Company’s named executive officers on an annual basis until the next stockholder vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers.
4. Approval of an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of our issued and outstanding shares of common stock at a ratio ranging from 1-for-15 to 1-for-50, with the exact ratio and timing, if at all, to be determined by our Board of Directors, in its sole discretion. The charter amendment to effectuate the reverse stock split was approved.
| For | Against | Abstain | Broker Non-Vote | |||
| 58,138,876 | 785,970 | 45,196 | N/A |
5. Approval of an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to designate the Class B common stock, with each share of Class B common stock entitled to 20 votes per share. The amendment to designate the Class B common stock was approved.
| For | Against | Abstain | Broker Non-Vote | |||
| 51,739,973 | 4,938,305 | 9,327 | 2,282,437 |
6. Ratification of the appointment of MaloneBailey LLP as the Company’s independent registered public accounting firm for 2026. The appointment was ratified.
| For | Against | Abstain | Broker Non-Vote | |||
| 58,514,997 | 137,804 | 317,241 | N/A |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Picard Medical, Inc. | |
|
|
By: |
/s/ Georgina Smith
|
|
Name:
|
Georgina Smith
|
|
| Title: |
Chief Accounting Officer
|
|
Dated: July 21, 2026